UNIQURE N.V. news, videos and press releases - Page 7
For more news please use our advanced search feature.
UNIQURE N.V. - More news...
UNIQURE N.V. - More news...
- uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
- uniQure Announces Pricing of its Public Offering
- uniQure Announces Proposed Public Offering
- uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
- uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
- uniQure Announces to Present at Multiple Conferences in May
- uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
- uniQure to Participate in Multiple Conferences in March
- uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
- uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress
- uniQure Announces Multiple Company Presentations at Upcoming November Conferences
- uniQure Announces Closing of its Public Offering
- uniQure Announces Pricing of its Public Offering
- uniQure Announces Proposed Public Offering
- uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)
- uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
- uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin
- uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease
- uniQure Announces Company Presentations at Upcoming October Conferences
- uniQure Announces Company Participation at Citi Healthcare Conference
- uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
- uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
- uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
- uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
- uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
- uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress
- uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies
- uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
- uniQure Announces Company Presentation at Jefferies Healthcare Conference
- uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B
